Jake Van Naarden

“We're really excited about the presence that we have in breast cancer historically and going forward. I think the three most important targets in breast cancer are the estrogen receptor CDK4-6 and PI3 kinase alpha.”

“So as Dan mentioned in the prepared remarks, we conducted a preplanned interim analysis of MONARCH-E, as we had talked about earlier in the year that we were going to do that.”

“We submit requests for company-sponsored guidelines that align with the labeling indications we expect to receive. We will do this regarding BTK-pretreated relapsed/refractory mantle cell lymphoma as well.”

“Our view of our program in the landscape hasn’t changed materially in light of recent competitor announcements. We have yet to see the full data from those companies, and in at least one case the management commentary suggested underpowered Phase II studies showing trends but not definitive results.”